Jade Biosciences (JBIO) Net Income towards Common Stockholders (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$40.5 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 5.98% year-over-year to -$40.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$202.1 million (down 58.43% YoY) and the FY2025 annual result came in at $178000.0, up 100.26% from the prior year.
• Net Income towards Common Stockholders declined to -$40.5 million in Q1 2026, from -$35.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$10.9 million in Q1 2022 to a low of -$118.1 million in Q1 2024.
• A 5-year average of -$43.4 million and a median of -$40.5 million in 2026 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 681.05% — and 2025, when it soared 67.68%.
• Tracing JBIO's Net Income towards Common Stockholders over 5 years: stood at -$15.8 million in 2022, then slumped by 40.57% to -$22.2 million in 2023, then slumped by 111.76% to -$47.0 million in 2024, then advanced by 25.54% to -$35.0 million in 2025, then dropped by 15.65% to -$40.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$40.5 million (Q1 2026), -$35.0 million (Q4 2025), and -$56.7 million (Q3 2025), per Business Quant data.